3,4-DimethoxybenzenepropanamineCAS# 14773-42-3 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 14773-42-3 | SDF | Download SDF |
PubChem ID | 2281053 | Appearance | Cryst. |
Formula | C11H17NO2 | M.Wt | 195.26 |
Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | 3-(3,4-dimethoxyphenyl)propan-1-amine | ||
SMILES | COC1=C(C=C(C=C1)CCCN)OC | ||
Standard InChIKey | WYYQSKUMIFPNFW-UHFFFAOYSA-N | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
3,4-Dimethoxybenzenepropanamine Dilution Calculator
3,4-Dimethoxybenzenepropanamine Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 5.1214 mL | 25.6069 mL | 51.2138 mL | 102.4275 mL | 128.0344 mL |
5 mM | 1.0243 mL | 5.1214 mL | 10.2428 mL | 20.4855 mL | 25.6069 mL |
10 mM | 0.5121 mL | 2.5607 mL | 5.1214 mL | 10.2428 mL | 12.8034 mL |
50 mM | 0.1024 mL | 0.5121 mL | 1.0243 mL | 2.0486 mL | 2.5607 mL |
100 mM | 0.0512 mL | 0.2561 mL | 0.5121 mL | 1.0243 mL | 1.2803 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 6-O-(3'',4''-Dimethoxycinnamoyl)catalpol
Catalog No.:BCN1655
CAS No.:147714-71-4
- 8-(3-Chlorostyryl)caffeine
Catalog No.:BCC7640
CAS No.:147700-11-6
- WIN 18446
Catalog No.:BCC6273
CAS No.:1477-57-2
- 2-Amino-4-methylbenzothiazole
Catalog No.:BCC8533
CAS No.:1477-42-5
- ZM 226600
Catalog No.:BCC6831
CAS No.:147695-92-9
- Magnolianin
Catalog No.:BCN3985
CAS No.:147663-91-0
- Calcipotriol monohydrate
Catalog No.:BCC1445
CAS No.:147657-22-5
- 5-Chloro-4-methoxy-2-oxo-1,2-dihydropyridine-3-carbonitrile
Catalog No.:BCC8744
CAS No.:147619-40-7
- Novobiocin Sodium
Catalog No.:BCC4812
CAS No.:1476-53-5
- ID-8
Catalog No.:BCC4787
CAS No.:147591-46-6
- DiMNF
Catalog No.:BCC3900
CAS No.:14756-24-2
- Racemodine
Catalog No.:BCN2023
CAS No.:147554-28-7
- Fmoc-O-Phospho-Tyr-OH
Catalog No.:BCC3563
CAS No.:147762-53-6
- Repaglinide ethyl ester
Catalog No.:BCC9135
CAS No.:147770-06-7
- L-161,982
Catalog No.:BCC7393
CAS No.:147776-06-5
- DCG IV
Catalog No.:BCC5691
CAS No.:147782-19-2
- ω-Conotoxin MVIIC
Catalog No.:BCC5699
CAS No.:147794-23-8
- Santacruzamate A (CAY10683)
Catalog No.:BCC5488
CAS No.:1477949-42-0
- Cefcapene pivoxil hydrochloride
Catalog No.:BCC8906
CAS No.:147816-24-8
- Siramesine
Catalog No.:BCC4304
CAS No.:147817-50-3
- Niazimicin
Catalog No.:BCN7641
CAS No.:147821-49-6
- Niazinin
Catalog No.:BCN7623
CAS No.:147821-57-6
- Filic-3-en-25-al
Catalog No.:BCN6445
CAS No.:147850-78-0
- CA-074 Me
Catalog No.:BCC3649
CAS No.:147859-80-1
Superior Canal Dehiscence Syndrome Affecting 3 Families.[Pubmed:28384775]
JAMA Otolaryngol Head Neck Surg. 2017 Jul 1;143(7):656-662.
Importance: Superior canal dehiscence syndrome (SCDS) is an increasingly recognized cause of hearing loss and vestibular symptoms, but the etiology of this condition remains unknown. Objective: To describe 7 cases of SCDS across 3 families. Design, Setting, and Participants: This retrospective case series included 7 patients from 3 different families treated at a neurotology clinic at a tertiary academic medical center from 2010 to 2014. Patients were referred by other otolaryngologists or were self-referred. Each patient demonstrated unilateral or bilateral SCDS or near dehiscence. Interventions: Clinical evaluation involved body mass index calculation, audiometry, cervical vestibular evoked myogenic potential testing, electrocochleography, and multiplanar computed tomographic (CT) scan of the temporal bones. Zygosity testing was performed on twin siblings. Main Outcomes and Measures: The diagnosis of SCDS was made if bone was absent over the superior semicircular canal on 2 consecutive CT images, in addition to 1 physiologic sign consistent with labyrinthine dehiscence. Near dehiscence was defined as absent bone on only 1 CT image but with symptoms and at least 1 physiologic sign of labyrinthine dehiscence. Results: A total of 7 patients (5 female and 2 male; age range, 8-49 years) from 3 families underwent evaluation. Family A consisted of 3 adult first-degree relatives, of whom 2 were diagnosed with SCDS and 1 with near dehiscence. Family B included a mother and her child, both of whom were diagnosed with unilateral SCDS. Family C consisted of adult monozygotic twins, each of whom was diagnosed with unilateral SCDS. For all cases, dehiscence was located at the arcuate eminence. Obesity alone did not explain the occurrence of SCDS because 5 of the 7 cases had a body mass index (calculated as weight in kilograms divided by height in meters squared) less than 30.0. Conclusions and Relevance: Superior canal dehiscence syndrome is a rare, often unrecognized condition. This report of 3 multiplex families with SCDS provides evidence in support of a potential genetic contribution to the etiology. Symptomatic first-degree relatives of patients diagnosed with SCDS should be offered evaluation to improve detection of this disorder.
Vitamin D reduces the inflammatory response by Porphyromonas gingivalis infection by modulating human beta-defensin-3 in human gingival epithelium and periodontal ligament cells.[Pubmed:28384529]
Int Immunopharmacol. 2017 Jun;47:106-117.
Periodontitis is a multifactorial polymicrobial infection characterized by a destructive inflammatory process. Porphyromonas gingivalis, a Gram-negative black-pigmented anaerobe, is a major pathogen in the initiation and progression of periodontitis; it produces several virulence factors that stimulate human gingival epithelium (HGE) cells and human periodontal ligament (HPL) cells to produce various inflammatory mediators. A variety of substances, such as vitamin D, have growth-inhibitory effects on some bacterial pathogens and have shown chemo-preventive and anti-inflammatory activity. We used a model with HGE and HPL cells infected with P. gingivalis to determine the influence of vitamin D on P. gingivalis growth and adhesion and the immunomodulatory effect on TNF-alpha, IL-8, IL-12 and human-beta-defensin 3 production. Our results demonstrated, firstly, the lack of any cytotoxic effect on the HGE and HPL cells when treated with vitamin D; in addition, vitamin D inhibited P. gingivalis adhesion and infectivity in HGE and HPL cells. Our study then showed that vitamin D reduced TNF-alpha, IL-8, IL-12 production in P. gingivalis-infected HGE and HPL cells. In contrast, a significant upregulation of the human-beta-defensin 3 expression in HGE and HPL cells induced by P. gingivalis was demonstrated. Our results indicate that vitamin D specifically enhances the production of the human-beta-defensin 3 antimicrobial peptide and exerts an inhibitory effect on the pro-inflammatory cytokines, thus suggesting that vitamin D may offer possible therapeutic applications for periodontitis.
Synthesis, biological evaluation and molecular modeling of 2-Hydroxyisoquinoline-1,3-dione analogues as inhibitors of HIV reverse transcriptase associated ribonuclease H and polymerase.[Pubmed:28384548]
Eur J Med Chem. 2017 Jun 16;133:85-96.
Human immunodeficiency virus (HIV) reverse transcriptase (RT) associated ribonuclease H (RNase H) remains the only virally encoded enzymatic function not clinically validated as an antiviral target. 2-Hydroxyisoquinoline-1,3-dione (HID) is known to confer active site directed inhibition of divalent metal-dependent enzymatic functions, such as HIV RNase H, integrase (IN) and hepatitis C virus (HCV) NS5B polymerase. We report herein the synthesis and biochemical evaluation of a few C-5, C-6 or C-7 substituted HID subtypes as HIV RNase H inhibitors. Our data indicate that while some of these subtypes inhibited both the RNase H and polymerase (pol) functions of RT, potent and selective RNase H inhibition was achieved with subtypes 8-9 as exemplified with compounds 8c and 9c.